These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2883335)

  • 1. Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats.
    Wambebe C
    Jpn J Pharmacol; 1987 Feb; 43(2):121-8. PubMed ID: 2883335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
    Worms P
    Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.
    Costall B; Naylor RJ
    Psychopharmacologia; 1975 Jul; 43(1):69-74. PubMed ID: 1172258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity.
    Usuda S; Nishikori K; Noshiro O; Maeno H
    Psychopharmacology (Berl); 1981; 73(2):103-9. PubMed ID: 6112770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Eur J Pharmacol; 1982 Jun; 81(1):1-9. PubMed ID: 6889533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050).
    Usuda S; Sano K; Maeno H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):68-78. PubMed ID: 43118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
    Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D
    Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of action of substituted benzamide drugs.
    Köhler C; Ogren SO; Fuxe K
    Acta Psychiatr Scand Suppl; 1984; 311():125-37. PubMed ID: 6142588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism by sulpiride of three apomorphine-induced effects in rodents.
    Puech AJ; Simon P; Boissier JR
    Eur J Pharmacol; 1976 Apr; 36(2):439-41. PubMed ID: 945169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice.
    Yurek DM; Randall PK
    Life Sci; 1985 Nov; 37(18):1665-73. PubMed ID: 4058245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of central stimulating effects between ephedrine and apomorphine].
    Li Q; Li BH
    Zhongguo Yao Li Xue Bao; 1991 Sep; 12(5):468-71. PubMed ID: 1819906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.
    Asmakova LS; Kalinina TS; Ostrovskaya RU; Gudasheva TA; Zaitseva NI; Bondarenko NA; Voronina TA; Seredenin SB
    Pharmacol Biochem Behav; 1999 Oct; 64(2):359-62. PubMed ID: 10515313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.
    Owolabi AR; Akanmu MA; Ukponmwan OE
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul; 378(1):117-24. PubMed ID: 18408917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of some atypical neuroleptics on apomorphine-induced behaviors as a measure of their relative potencies in blocking presynaptic versus postsynaptic dopamine receptors.
    Robertson A; MacDonald C
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1639-43. PubMed ID: 2874567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats.
    Balsara JJ; Nandal NV; Burte NP; Jadhav JH; Chandorkar AG
    Psychopharmacology (Berl); 1984; 82(3):237-40. PubMed ID: 6425907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
    Köhler C; Ogren SO; Haglund L; Angeby T
    Neurosci Lett; 1979 Jun; 13(1):51-6. PubMed ID: 572522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.